Evidence map›Paper›PMID 39630349›Full record

ReviewInternational journal of hematology2025

Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature.

Junki Inamura, Takeshi Taketani, Miho Mochida, Tsukimi Goto, Ritsuro Suzuki, Sho Igarashi, Nodoka Tsukada, Masayo Yamamoto, Motohiro Shindo, Kazuya Sato

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Junki InamuraDepartment of Hematology/Oncology, Asahikawa Kosei Hospital, Asahikawa, Japan. j_inamura@hotmail.com.ORCID http://orcid.org/0009-0005-2267-4473
Takeshi TaketaniDepartment of Pediatrics, Faculty of Medicine, Shimane University, Izumo, Japan.
Miho MochidaRegenerative Medicine Center, Shimane University Hospital, Izumo, Japan.
Tsukimi GotoClinical Laboratory Division, Shimane University Hospital, Izumo, Japan.
Ritsuro SuzukiDepartment of Hematology, Shimane University Hospital, Izumo, Japan.
Sho IgarashiDepartment of Hematology/Oncology, Asahikawa Kosei Hospital, Asahikawa, Japan.
Nodoka TsukadaDepartment of Hematology/Oncology, Asahikawa Kosei Hospital, Asahikawa, Japan.
Masayo YamamotoDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
Motohiro ShindoDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
Kazuya SatoDepartment of Hematology/Oncology, Asahikawa Kosei Hospital, Asahikawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a rare case of acute myeloid leukemia (AML) with t(11;12)(p15;q13) and NUP98::RARG, which seems to be involved in the development of AML. The morphological features were similar to those of classic acute promyelocytic leukemia (APL), but unlike classic APL, this leukemia was resistant to treatment with all-trans retinoic acid (ATRA). We decided to use standard chemotherapy for AML with monitoring of minimal residual disease (MRD) by qualitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis for NUP98::RARG mRNA. Although MRD disappeared after induction chemotherapy, it later reappeared, and hematological relapse occurred during subsequent chemotherapies. The patient received haploidentical hematopoietic stem cell transplantation while not in remission and achieved a second molecular remission. However, relapse occurred 4 months after transplantation. The specific mechanism of ATRA resistance in this unique case of AML remains unclear, and no standard treatment has been determined. This is the first case report of AML with NUP98::RARG rearrangement in Japan. Qualitative RT-PCR analysis for NUP98::RARG mRNA was helpful for the accurate diagnosis and evaluation of MRD to choose an adequate treatment for this type of AML.

Indexed as

Leukemia, Myeloid, AcuteNuclear Pore Complex ProteinsOncogene Proteins, FusionChromosomes, Human, Pair 11Chromosomes, Human, Pair 12Gene RearrangementHematopoietic Stem Cell TransplantationHumansNeoplasm, ResidualReceptors, Retinoic AcidTranslocation, GeneticTretinoinNuclear Pore Complex ProteinsNup98 protein, humanOncogene Proteins, FusionReceptors, Retinoic AcidTretinoinAcute promyelocytic leukemiaHaploidentical transplantationNUP98RARG

Identifiers

PMID39630349

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.